HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb Recognizes OTC Monograph Woes During Confirmation Hearing

This article was originally published in The Rose Sheet

Executive Summary

FDA commissioner nominee Scott Gottlieb agreed that the OTC drug monographs constitute “a system that is in need of modernization” during his April 5 confirmation hearing before the Senate HELP Committee. HELP Democrats tested the FDA commissioner nominee’s willingness to “stand up to the administration” and probed potential conflicts of interest.

You may also be interested in...



OTC Monograph Reform May Have To Launch Without User Fees, Senate Sponsor Says

"We believe that we're going to get this done," but "it's possible that ... language authorizing the collection of user fees is not included in this year's appropriation legislation," says Sen. Bob Casey during HELP Committee's confirmation hearing for FDA commissioner nominee Stephen Hahn.

Former FDA Commissioners Push For Sharpless Nomination, Confirmation

Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.

OTC Monograph User Fees Up To $34M Floated In Senate Discussion Draft

Bulk of user fees would be raised through facility fees, under Sens. Isakson and Casey’s discussion draft, but there's little time to add the changes to FDA user fee reauthorization bills already moving in Congress.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel